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Objectives. The objective of this study was to identify predictors
of major adverse cardiac events after successful coronary angio-
plasty.
Background. The acute complications of angioplasty are related
to baseline clinical and angiographic variables, and early compli-
cations adversely affect long-term outcome. However, the predic-
tors of enduring success after uncomplicated angioplasty are less
well defined.
Methods. Of 4,098 patients undergoing angioplasty in the
Hirulog Angioplasty Study, 3,899 (95%) had a successful proce-
dure without in-hospital death, emergent bypass surgery or
clinical evidence of myocardial infarction. Baseline and proce-
dural variables for these 3,899 patients were examined.
Results. Major adverse cardiac events occurred in 22% of the
patients with initially successful procedures at 6 months: death in
1%, myocardial infarction in 2% and repeat revascularization in
21%. Univariable predictors of increased events included success-
ful salvage from abrupt vessel closure (p < 0.001), emergency
stenting (p < 0.001), multilesion angioplasty (p < 0.001), diabetes
(p 5 0.02), target lesion in the left anterior descending artery (p 5
0.02), unstable angina (p 5 0.03) and smaller final luminal
diameter (p 5 0.04). There was a trend toward increased events
among patients with prior angioplasty (p 5 0.08), but asymptom-
atic elevation of the creatine kinase was not predictive (p 5 0.5).
In a multivariable model, abrupt vessel closure was the strongest
independent predictor of major adverse cardiac events at 6
months (p < 0.001; odds ratio [95% confidence interval] 5 3.6
[2.5 to 5.1]), while multivessel angioplasty, target lesion in the left
anterior descending artery and diabetes also remained indepen-
dent predictors (all p <2 0.02).
Conclusions. This analysis suggests that “uncomplicated”
abrupt vessel closure is a powerful predictor of adverse clinical
outcome following successful angioplasty. Improved techniques to
reduce abrupt closure during angioplasty are thus urgently
needed, and patients who experience “uncomplicated” closure
require closer surveillance during follow-up.
(J Am Coll Cardiol 1999;33:73–8)
©1998 by the American College of Cardiology
Percutaneous coronary revascularization procedures are now
widely applied to treat acute coronary syndromes. Much
attention has centered on the acute results and associated
complications of these procedures (1–16), but few studies
See page 79
(17–24) have focused on predictors of enduring clinical success
during the ensuing 6 months, a more relevant end point in
clinical practice. Long-term success is clearly reduced when
major ischemic complications occur at the time of the initial
procedure (2,3). The predictors of 6 month clinical outcome
among successfully treated patients without in-hospital com-
plications remain uncertain, however. We utilized data from
the recent Hirulog Angioplasty Study (25) to examine the
predictors of clinical outcome at 6 months following successful
percutaneous coronary revascularization.
Methods
Study population. In the Hirulog Angioplasty Study 4,098
patients undergoing conventional balloon angioplasty for the
treatment of unstable angina between March 24, 1993 and July
15, 1994 were randomized to treatment with heparin or
bivalirudin in a double-blind fashion for 18 to 24 h (25).
Unstable angina was defined as angina of new onset, crescendo
angina, rest pain or angina within 2 weeks of a myocardial
infarction (MI).
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Hospital outcome was analyzed for all 4,098 patients. In this
substudy, 6-month clinical outcome was analyzed for the 3,899
of 4,098 patients (95%) who underwent successful coronary
intervention without a major ischemic complication in-
hospital. Because bivalirudin did not produce a significant
treatment effect in the study (25), all patients were combined
as a single group for the purposes of this analysis.
Definitions. Major ischemic complications were defined as
in-hospital death, MI or emergent coronary artery bypass graft
surgery (CABG). The definition of MI was a rise in the total
serum creatine kinase (CK) concentration above twice the
upper limit of normal with an MB fraction of at least 4.0% in
association with either ischemic chest pain lasting longer than
30 min, or a new two-step Q wave change (according to the
Minnesota code) (26), persistent ST segment or T wave
changes or a new left bundle branch block. Reelevation of the
total or CK-MB to above the previous nadir in association with
ischemic chest pain or the defined ischemic electrocardio-
graphic changes was also classified as reinfarction. Event-free
survival at 6 months was defined as freedom from major
adverse cardiac events (MACE), defined as death, MI or
repeat revascularization.
A procedure was defined as successful if it was performed
without a major in-hospital ischemic complication. Abrupt
vessel closure (AVC) included both threatened and estab-
lished closure. Threatened closure after initially successful
dilation of the target lesion was defined as a recurrent stenosis
of more than 50% with flow less than Thrombolysis in
Myocardial Infarction trial (TIMI) grade 3 (27) requiring
intracoronary stenting, thrombolytic therapy or repeat cardiac
catheterization (28,29). Established AVC after initially suc-
cessful dilation was defined as total or subtotal occlusion of the
target lesion with impaired flow to TIMI grade 0 or 1 (2).
“Complicated” AVC was defined as threatened or established
closure that led to a major in-hospital ischemic complication.
“Uncomplicated” AVC was a closure that was successfully
reversed without a resultant major in-hospital ischemic com-
plication. In the angiographic analysis, thrombus was defined
as a filling defect, haze or ulceration at the lesion site, or a total
occlusion.
Data collection. Clinical follow-up was obtained at 3 and 6
months postprocedure. Measurement of the total CK was
performed at 8 and 16 h after angioplasty, with MB determi-
nations done if the total CK was elevated. Of 4,098 patients in
the trial, 4,068 (99%) had at least one CK measurement after
angioplasty. All data were submitted to the data coordinating
center (ClinTrials Research, Research Triangle Park, NC) and
were verified for accuracy against source documents by clinical
monitors from ClinTrials.
Angiograms were reviewed at the core angiographic labo-
ratory by experienced angiographers blinded to treatment
assignment using electronic digital calipers according to previ-
ously validated methods (30). Of 4,098 patients in the trial,
4,056 (99%) had films reviewed at the core laboratory. Angio-
grams were analyzed on 368 of the 378 (97%) patients who
experienced AVC during the study.
Statistical analysis. Categorical variables were compared
using Fisher exact test or Pearson chi-square test where
appropriate. Student t test was used to compare continuous
variables between groups. Logistic regression, incorporating
univariates with at least borderline significance (p , 0.10), was
used to determine predictors of ischemic complications during
the 6 months after successful angioplasty. Statistical analysis
was performed using SPSS. Baseline data were unavailable on
3 of 4,098 patients (0.1%) who underwent angioplasty, and
follow-up data were incomplete for 195 patients (5%). Angio-
graphic data for 42 patients (1%) were unavailable.
Results
Clinical and angiographic characteristics. Of 4,098 pa-
tients undergoing angioplasty in the trial, 83% had unstable
angina and 17% had post-MI angina (Table 1). Rest angina
occurred in 64%. Multivessel coronary disease was identified
in 47%, and 17% underwent multilesion angioplasty (Table 2).
Hospital outcome. Angioplasty was successful without a
major in-hospital ischemic complication in 3,899 of 4,098
patients (95%). Death occurred in 13 (0.3%), MI in 145 (4%),
emergency CABG in 70 (2%) and at least one of these major
complications occurred in 199 patients (5%). The majority of
complications followed an episode of abrupt vessel closure, but
not all AVCs resulted in a major ischemic event. Of the 4,098
patients in the study, 378 patients (9%) experienced a total of
397 episodes of AVC. Although the milder form of “threat-
ened” vessel closure predominated (240 of 397 episodes
[60%]), both threatened and established closure sharply in-
Abbreviations and Acronyms
AVC 5 Abrupt vessel closure
CABG 5 Coronary artery bypass graft surgery
CK 5 Creatine kinase
MACE 5 Major adverse cardiac events
MI 5 myocardial infarction
TIMI 5 Thrombolysis in Myocardial Infarction trial
Table 1. Baseline Clinical Characteristics for 4,098 Patients
Undergoing Coronary Angioplasty for Unstable or
Postinfarction Angina
Characteristic n (%)
Age (mean in yr 6 SD) 62 6 11
Female gender 1,322 (32)
Diabetes 864 (21)
Unstable angina 3,394 (83)
Rest pain 2,629 (64)
Post-MI angina 704 (17)
Prior angioplasty 1,077 (26)
Prior CABG 390 (10)
Heparin pretreatment 1,519 (37)
CABG 5 coronary artery bypass graft surgery; MI 5 myocardial infarction.
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creased the likelihood of major ischemic complications. Death,
MI or emergency CABG occurred in 71 of 3,720 patients (2%)
without vessel closure, in 48 of 240 (20%) with threatened
closure and in 80 of 138 (58%) with established closure (p ,
0.001). Thus, by definition 128 of 378 patients with threatened
or established closure sustained “complicated” AVC, while the
remaining 250 patients had “uncomplicated” AVC (Fig. 1).
Abrupt closure was managed with emergency stent place-
ment in 31% of patients with complicated AVC, as compared
with 44% of patients with uncomplicated AVC (p 5 0.01).
Filling defects were detected during the procedure in 20% of
patients with complicated AVC and in 16% of those with
uncomplicated AVC, compared with only 3% of patients never
sustaining closure (p , 0.001).
Among the 3,899 patients with successful angioplasty, 155
(4%) developed an elevation of the CK to greater than twice
the upper limit of normal without ischemic symptoms or
electrocardiographic changes. These were not classified as MI
events according to the predetermined definition. Asymptom-
atic elevations of CK were detected in 139 of 3,649 (0.4%)
successful procedures without an episode of threatened or
established AVC, compared with 16 of 250 (6%) procedures
with uncomplicated AVC (p 5 0.04).
Follow-up after successful angioplasty. Clinical status at 6
months was available for 3,704 of the 3,899 patients (95%) with
successful index procedures. The rate of follow-up was equal
for those with and without AVC (both 95%) during the index
procedure. Patients without follow-up were younger (59 6 12
vs. 62 6 11 years; p , 0.001) and had a lower prevalence of
prior angioplasty (17% vs. 27%; p 5 0.002) compared to those
with follow-up. Otherwise the two groups were similar.
Major adverse cardiac events occurred by 6 months in 825
of 3,704 (22%) patients, including death in 44 (1%), MI in 82
(2%) and repeat revascularization in 770 (21%). Clinical and
angiographic predictors of an increased incidence of MACE in
follow-up (Table 3) included AVC (p , 0.001), requirement
for stent placement during the index procedure (p , 0.001),
multilesion angioplasty (p , 0.001), diabetes (p 5 0.02),
angioplasty of the left anterior descending artery (p 5 0.02),
unstable angina as opposed to post-MI angina (p 5 0.03) and
a smaller postprocedural luminal diameter (p 5 0.04). There
was also a trend for increased MACE among patients who had
undergone prior angioplasty (p 5 0.08). Lesion length, refer-
ence diameter, final percent stenosis, residual stenosis of
greater than 50%, persistent dissection at completion of the
procedure and asymptomatic elevation of the CK were not
statistically significantly associated with increased events in
follow-up. In a multivariable analysis incorporating the univa-
riable predictors, AVC was the strongest independent predic-
tor of MACE at 6 months (p , 0.001; odds ratio [95%
confidence interval] 5 3.6 [2.5 to 5.1]), while multilesion
angioplasty, target lesion in the left anterior descending artery
and diabetes also remained independent predictors.
Of 238 patients with complete follow-up who had sustained
uncomplicated AVC during the index procedure, 105 (44%)
experienced an adverse clinical event by 6 months, compared
with 720 of the 3,466 successful patients (21%) who had no
AVC during angioplasty (p , 0.001; Table 4). The higher event
rate in the uncomplicated AVC cohort was driven by a
doubling of the rate of repeat revascularization (44% vs. 19%;
p , 0.001), whereas death and MI were not increased.
The 250 patients with uncomplicated AVC were less likely
to have undergone prior angioplasty than the 3,649 successfully
treated patients without abrupt closure (21% vs. 27%; p 5
0.05), but otherwise the two groups shared similar clinical
characteristics. By contrast, angiographic analysis suggested
that the lesions treated in patients with uncomplicated AVC
were significantly more complex than those in the other
successfully treated patients. These lesions were less often type
A (24% vs. 33%; p 5 0.001) or discrete (74% vs. 81%; p 5
0.01), they had a higher prevalence of filling defects (5% vs.
2%; p 5 0.01) or features suggestive of thrombus at baseline
(21% vs. 13%; p 5 0.001) and they had more severe stenoses
at the target site (74 6 15% vs. 71 6 16%; p 5 0.001). During
the procedure, patients with uncomplicated closure sustained
Figure 1. Flow diagram of patients’ in-hospital course in the Hirulog
Angioplasty Study. AVC 5 abrupt vessel closure. *“Uncomplicated”
abrupt vessel closure indicates that the abrupt closure event did not
result in a major ischemic complication (death, myocardial infarction
or emergent coronary artery bypass graft surgery). †“Complicated”
abrupt vessel closure indicates that the abrupt closure event did result
in a major ischemic complication (death, myocardial infarction or
emergent coronary artery bypass graft surgery).
Table 2. Baseline Angiographic Characteristics of 4,056 Patients
with Core Laboratory Analysis
Characteristic n (%)
Multivessel coronary disease 1914 (47)
Number of treated lesions
1 3,372 (83)
$2 684 (17)
Target lesion grade
Type A 1,311 (32)
Type B or C 2,745 (67)
Target lesion morphology
Total occlusion 286 (7)
Filling defect 95 (2)
Thrombus* 550 (14)
Eccentric 1,554 (38)
% stenosis (mean 6 SD) 71 6 16
*The presence of thrombus was indicated by angiographic evidence of total
occlusion, filling defect or hazy ulcerated lesion.
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more dissections (45% vs. 20%; p , 0.001), required more
stents (45% vs. 0.2%; p , 0.001) and had a higher incidence of
a residual stenosis greater than 50% by core angiographic
analysis (15% vs. 9%; p 5 0.002).
Discussion
In this study involving over 4,000 patients with unstable or
post-MI angina treated with conventional balloon angioplasty,
the most powerful predictor of clinical outcome during the 6
months following an otherwise successful procedure was an
episode of AVC. The 9% incidence of AVC in the current
study is higher than commonly reported and reflects the
inclusion of “threatened” along with established closure in our
prespecified definition. Of the 378 patients with threatened or
established AVC, 250 (66%) were successfully treated without
an in-hospital major ischemic event using repeat balloon
angioplasty or stenting, and were therefore considered “un-
complicated” by current definitions. Nevertheless, this group
of successfully “salvaged” patients experienced a significant
increase in MACE during 6 months of follow-up when com-
pared to patients who did not sustain closure or other compli-
cations during the index hospitalization (44% vs. 21%; p ,
0.001). Diabetes, multivessel angioplasty and angioplasty of the
left anterior descending artery were also independent predic-
tors of adverse outcome at 6 months, consistent with the well
established increased rate of restenosis in such patients
(19,31,32).
The prognostic significance of transient vessel closure dur-
ing angioplasty has previously been suggested by data from the
1985–1986 National Heart, Lung and Blood Institute Registry.
At 2 years of follow-up, patients with successfully reversed
AVC had reduced survival (92% vs. 96%) and increased repeat
revascularization rates (42% vs. 31%) compared to those
without transient occlusion (2). Tanaglia also documented an
increased rate of death, MI and repeat angioplasty by 1 year
among patients salvaged from abrupt closure at Duke (33).
Repeat revascularization procedures accounted for the
large increase in adverse events among patients with uncom-
plicated AVC in the present study (44% vs. 19% among those
without AVC; p , 0.001). This 44% rate is higher than the
13% incidence at 1 year observed by Abdelmeguid in a smaller
group of 88 patients with transient vessel closure (34). How-
ever, Abdelmeguid’s single center, retrospective analysis ex-
cluded patients treated with bailout stenting, which was re-
quired in 44% of our patients with uncomplicated AVC,
despite being officially discouraged by the study. The decision
to deploy a stent may have reflected more complicated vessel
disruption, portending a higher risk prognosis than for AVC
manageable with repeat balloon angioplasty alone. Ab-
delmeguid’s report was also not restricted to patients with
unstable angina. The 1-year repeat revascularization rate of
only 11% among patients without AVC in Abdelmeguid’s
study contrasts with the 20% to 28% incidence at 6 months
observed in the Hirulog study and many other recent multi-
center trials of balloon angioplasty for unstable angina
(22,35,36), suggesting possible differences in the patient pop-
ulations.
Several explanations for the adverse prognostic significance
of uncomplicated AVC are possible. Patients with “uncompli-
cated” AVC had more complex target lesions and achieved less
optimal postprocedural angiographic results than patients who
had successful angioplasty with no abrupt closure event. Un-
planned stenting was also required in 44% of patients with
“uncomplicated” AVC. Bailout stenting is highly successful in
Table 3. Predictors of Major Ischemic Events in Follow-up in 3,899 Patients Without
In-Hospital Complications
Characteristic
Feature
Present*
Feature
Absent*
Univariable
p Value
Multivariable p
Value (Odds
Ratio [CI])
Prior angioplasty (%) 24 21 0.08 0.07 (1.2 [1.0 to 1.4])
Unstable angina (%) 23 19 0.03 0.09 (1.2 [1.0 to 1.7])
LAD location (%) 24 21 0.02 0.004 (1.3 [1.1 to 1.5])
Diabetes (%) 25 20 0.01 0.01 (1.3 [1.1 to 1.6])
.1 target lesion (%) 28 21 , 0.001 , 0.001 (1.5 [1.3 to 1.7])
Stent (%) 38 21 , 0.001 0.17 (0.7 [0.4 to 1.2])
Any AVC (%) 44 20 , 0.001 0.001 (3.6 [2.5 to 5.1])
*Percentage of patients with features present or absent who sustained a major ischemic event in follow-up. A total
of 195 patients (5% in each group) had incomplete or missing follow-up data. AVC 5 abrupt vessel closure; CI 5
confidence interval; LAD 5 left anterior descending artery.
Table 4. Cumulative Rates of Major Adverse Cardiac Events at
Six Months Follow-up Among 3,899 Patients Without
In-Hospital Complications
Characteristic
No AVC and No
Complication
(n 5 3,466)
Uncomplicated
AVC (n 5 238) p
Death (%) 1 0.4 0.27
Myocardial infarction (%) 2 3 0.40
Revascularization (%) 19 44 , 0.001
Any ischemic event (%) 21 44 , 0.001
A total of 195 patients (5% in each group) had incomplete or missing
follow-up data. Major adverse cardiac events include death, myocardial infarc-
tion or repeat revascularization. Revascularization denotes bypass operation or
repeat percutaneous coronary intervention. AVC 5 abrupt vessel closure.
76 PIANA ET AL. JACC Vol. 33, No. 1
PREDICTORS OF CLINICAL OUTCOME AFTER PTCA January 1999:73–8
the acute setting, but it is accompanied by higher rates of
subacute thrombosis and restenosis than after elective stenting
(21,37–40). Periprocedural myonecrosis also occurred signifi-
cantly more frequently following “uncomplicated” AVC. Even
minor elevations of the CK after coronary intervention have
been found by some investigators to predict reduced event-free
survival (34,41–43).
The significant increase in the rate of MACE among
patients with uncomplicated AVC cannot be fully explained by
adverse morphologic features or more complex interventions,
however. In the present study, neither lesion morphology nor
elevation of the CK to above twice the upper limit of normal
among patients with successful angioplasty was predictive of
MACE at 6 months. In addition, multivariable analysis dem-
onstrated that the AVC event itself was the most powerful
independent predictor of MACE in follow-up, with an odds
ratio of 3.6. Thus, although clinical and angiographic charac-
teristics are important in assessing patients’ risk following
angioplasty, the occurrence of transient coronary occlusion
during the procedure appears to have a significant impact on
outcome independent of these other data.
Limitations. This was a retrospective analysis of subgroups
from the Hirulog Angioplasty Trial, which was limited to
patients with unstable angina and was completed prior to
widespread use of glycoprotein IIb/IIIa inhibitors in coronary
intervention. The prognostic implications of “uncomplicated”
AVC may be different in stable angina or when IIb/IIIa
antagonists are utilized. Elevation of the CK was detected in
only 0.4% of non-AVC patients and 6% of AVC patients
following successful angioplasty, possibly reflecting less strin-
gent surveillance than in some other studies. Stricter surveil-
lance and routine measurement of the CK-MB isoform may
have uncovered a greater prognostic significance of enzyme
elevation. Given the high prevalence of salvage stenting among
patients with uncomplicated abrupt vessel closure, these re-
sults cannot necessarily be extrapolated to a population with
transient occlusion that can be reversed with balloon angio-
plasty alone.
Conclusions. Abrupt vessel closure during angioplasty for
unstable or post-MI angina has a significant, independent,
adverse effect on clinical outcome at 6 months. This holds true
even when the closure does not cause a major ischemic event
acutely, and is thus traditionally considered “uncomplicated”
by the operator at the time of the procedure. Abrupt closure
may thus serve as a general marker that incorporates unfavor-
able clinical characteristics, adverse features of the lesion or a
less satisfactory angiographic result when the closure is sal-
vaged. Fortunately, such uncomplicated abrupt closure events
do not appear to increase subsequent rates of myocardial
infarction or death. They do portend a significant increase in
the need for repeat revascularization by 6 months, however. As
interventional techniques are applied to more severely ill
patients with increasingly complex coronary artery disease, the
potential exists for the rates of transient or established vessel
closure to rise. Acute complication rates may not reflect these
instances of transient occlusion, because two thirds of such
events can be reversed using the current interventional arma-
mentarium without a recognized major ischemic event. Never-
theless, our analysis suggests that these salvaged patients
constitute a population at higher risk for subsequent ischemic
events. Thus, in approaching increasingly difficult scenarios for
coronary intervention, techniques designed to reduce rates of
abrupt closure should be applied when possible, and the
potential medical and economic implications of even transient
occlusion should be considered prior to attempts at percuta-
neous revascularization.
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